Search Results

KCCQ Studied to Assess TAVR Mortality Risk

December 10, 2015—Suzanne V. Arnold, MD, et al conducted an investigation of the association of patient-reported health status with long-term mortality after transcatheter aortic valve replacement (TAVR) in the Society of Thoracic Surgeons (STS)/American College of Cardiology (ACC) Transcatheter Valve Therapy (TVT) Registry. The findings were published online ahead of print in Circulation: Cardiovascular Interventions.

Risk Models Evaluated for Predicting Poor Outcome After TAVR

October 17, 2016—In Journal of the American College of Cardiology (JACC), Suzanne V. Arnold, MD, et al published a study that examined how previously developed poor outcome risk models for transcatheter aortic valve replacement (TAVR) performed in an external data set and explored the incremental contribution of geriatric domains to model performance (2016;68:1868–1877). 

Evaluation of PARTNER Trial Shows High Costs of Periprocedural Complications With TAVR

December 19, 2014—Results from an evaluation of costs of periprocedural complications in patients treated with transcatheter aortic valve replacement (TAVR) in the PARTNER trial were published by Suzanne V. Arnold, MD, et al on behalf of the PARTNER investigators in Circulation: Cardiovascular Interventions (2014;7:829–836).

Abbott’s TriClip Evaluated in Quality-of-Life Analysis From TRILUMINATE Pivotal Trial

October 26, 2023—An in-depth health status analysis of the TRILUMINATE pivotal trial found that tricuspid transcatheter edge-to-edge repair (T-TEER) provided substantial benefits in terms of symptoms, functional status, and quality of life compared to medical therapy in patients with severe tricuspid regurgitation (TR).

Clinical Risk Model of 30-Day Mortality After TAVR Developed With Functional Status Measures

March 20, 2018—Investigators from the Society of Thoracic Surgeons (STS)/American College of Cardiology (ACC) Transcatheter Valve Therapy (TVT) Registry developed a clinical risk model for 30-day mortality after transcatheter aortic valve replacement (TAVR) that includes clinical data as well as health status and frailty.

Edwards’ Evoque System Evaluated in TRISCEND II for Clinical and QoL Benefits in Severe TR

November 7, 2024—Edwards Lifesciences Corporation recently announced that the company’s Evoque system demonstrated superiority compared to optimal medical therapy (OMT) alone for the 1-year primary endpoint of the TRISCEND II trial in the full cohort of 400 patients.